PharmaRadar360

PharmaRadar360

πŸ‡ΊπŸ‡ΈΒ·Aug 31Regulatory

Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)

FOR IMMEDIATE RELEASE - August 27, 2026 - Davie, Florida – Ana Salazar Modela Tu Cuerpo Inc. is reca...

Publisher

F
FDA MedWatch

USA

This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
FDA MedWatch
Region
USA
Scope
Regulatory
Published
August 31, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

FOR IMMEDIATE RELEASE - August 27, 2026 - Davie, Florida – Ana Salazar Modela Tu Cuerpo Inc. is reca...

Source route

Continue on fda.gov

Leave the platform to read the original full article on the publisher site.

Source: FDA MedWatch

Scope: Regulatory

Open original article
Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP) | PharmaRadar360